Related Experiment Video
Updated: Aug 2, 2026
12:21
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
Published on: November 26, 2015
Perilymph penetration of methotrexate in cats
Cancer Treatment Reports
|July 1, 1977
Summary
Leukemic infiltrates in the inner ear perilymph are common. This study shows that methotrexate, a chemotherapy drug, enters the perilymph slowly from the blood or cerebrospinal fluid in animal models.
Area of Science:
- Oto-neurology
- Pharmacology
- Oncology
Background:
- The inner ear perilymph is a potential site for leukemic or lymphomatous infiltrates.
- Blood-labyrinth and blood-cerebrospinal fluid barriers limit drug entry into the perilymph.
- Understanding drug penetration into the perilymph is crucial for treating inner ear malignancies.
Purpose of the Study:
- To investigate the entry of methotrexate into the perilymph.
- To quantify the attenuated penetration of methotrexate into the perilymph compartment.
- To assess methotrexate entry following different administration routes.
Main Methods:
- Experimental animal models were used.
- Intrathecal administration of methotrexate was performed.
- Intravenous administration of methotrexate was performed.
Main Results:
- Methotrexate demonstrated attenuated entry into the perilymph compartment.
- The penetration of methotrexate into the perilymph was significantly limited.
- Both intrathecal and intravenous routes showed restricted access to the perilymph.
Conclusions:
- The perilymph compartment exhibits a barrier limiting chemotherapy drug entry.
- Methotrexate penetration into the inner ear perilymph is restricted.
- Further strategies may be needed to achieve therapeutic concentrations in the perilymph for treating inner ear cancers.
